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D

evelopment of B lymphocytes proceeds through a series
of steps marked by Ig gene rearrangement as well as
ordered expression of transcription factors (1). Aberrant
expression of various transcription factors can predispose developing B cells to leukemia (2). Development of B cell progenitors
requires signaling through the IL-7R (3, 4). Productive rearrangement of the IgH locus in pro–B cells permits expression of
IgH protein and assembly with surrogate L chain components to
*Centre for Human Immunology, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6A 5C1, Canada; †Department of Animal
Care and Veterinary Services, University of Western Ontario, London, Ontario N6A
5C1, Canada; ‡Robarts Research Institute, University of Western Ontario, London,
Ontario N6A 5C1, Canada; xDepartment of Physiology and Pharmacology, University
of Western Ontario, London, Ontario N6A 5C1, Canada; and {Division of Genetics
and Development, Children’s Health Research Institute, Lawson Research Institute,
London, Ontario N6C 2R5, Canada
1

D.A.C. and L.S.X. contributed equally to this study.

Received for publication June 20, 2014. Accepted for publication November 4, 2014.
This work was supported by Canadian Institutes of Health Research Grant MOP106581 (to R.P.D.), a grant from the Leukemia and Lymphoma Society of Canada (to
R.P.D.), and by an Ontario Graduate Scholarship (to S.K.H.L.).
The sequences presented in this article have been submitted to the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE48891
and GSE 58128.
Address correspondence and reprint requests to Dr. Rodney P. DeKoter, Department
of Microbiology and Immunology, Schulich School of Medicine and Dentistry,
University of Western Ontario, London, ON N6A 5C1, Canada. E-mail address:
rdekoter@uwo.ca
The online version of this article contains supplemental material.
Abbreviations used in this article: DB, CD19+/+Spi1lox/loxSpib2/2; B-ALL, B cell acute
lymphoblastic leukemia; BM, bone marrow; BTK, Bruton tyrosine kinase; CD19CreDPB, CD19+/CreSpi1lox/loxSpib2/2; ChIP, chromatin immunoprecipitation;
ChIP-seq, chromatin immunoprecipitation sequencing; NSG, NOD/SCID/gc2/2;
qPCR, quantitative PCR; RT-qPCR, reverse transcription–quantitative PCR; WT,
wild-type.
Copyright Ó 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1401569

promote cell surface expression of a pre-BCR. Signaling through
the pre-BCR promotes cell cycle exit and differentiation into small
pre–B cells that initiate Ig k or l L chain rearrangement (5, 6).
Completion of functional Ig L chain rearrangement enables differentiation into B cells expressing a functional BCR.
Several lines of evidence suggest that pre-BCR signaling and
IL-7 signaling are mutually antagonistic. IL-7 signaling in pro–B/
pre–B cells impairs Igk rearrangement in a STAT5-dependent
manner (7). Pre–B cells are released from the differentiation block
induced by IL-7 by moving from microenvironments containing
high IL-7 concentrations to low IL-7 concentrations (5, 8). PreBCR signaling interferes with the IL-7 signaling pathway using
a mechanism that requires B cell linker protein (BLNK/SLP-65)
(9). Finally, upon differentiation into immature B cells, the Il7r
gene is permanently downregulated at the transcriptional level
using mechanisms that are as yet uncharacterized (10). In summary, functional opposition of the pre-BCR and IL-7 signaling
pathways is required for differentiation of large pre–B cells into
small pre–B cells and Ig L chain rearrangement. Mutations in
genes that impair this functional opposition can lead to loss of
genomic integrity and leukemia (5).
PU.1 and Spi-B are highly related transcription factors of the
E26 transformation–specific family. PU.1 and Spi-B are both expressed in developing B cells and have functional redundancy, likely
interacting with a similar set of binding sites in the genome (11,
12). Mutations in SPI1 encoding PU.1 are associated with relapsed
B cell acute lymphoblastic leukemia (B-ALL) (13). Repression of
the gene encoding Spi-B (Spib) was recently found to be associated with human precursor B-ALL (14) as well as with a mouse
model of B-ALL (15). Our laboratory showed that combined null
mutation of Spi1 and Spib in mice (CD19+/CreSpi1lox/loxSpib2/2
mice, called CD19-CreDPB mice in this study) leads to B-ALL at
a median age of 21 wk at 100% incidence (16). The tumor sup-
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Deletion of genes encoding the E26 transformation-specific transcription factors PU.1 and Spi-B in B cells (CD19-CreDPB mice)
leads to impaired B cell development, followed by B cell acute lymphoblastic leukemia at 100% incidence and with a median
survival of 21 wk. However, little is known about the target genes that explain leukemogenesis in these mice. In this study we found
that immature B cells were altered in frequency in the bone marrow of preleukemic CD19-CreDPB mice. Enriched pro–B cells
from CD19-CreDPB mice induced disease upon transplantation, suggesting that these were leukemia-initiating cells. Bone marrow cells from preleukemic CD19-CreDPB mice had increased responsiveness to IL-7 and could proliferate indefinitely in
response to this cytokine. Bruton tyrosine kinase (BTK), a negative regulator of IL-7 signaling, was reduced in preleukemic
and leukemic CD19-CreDPB cells compared with controls. Induction of PU.1 expression in cultured CD19-CreDPB pro–B cell
lines induced Btk expression, followed by reduced STAT5 phosphorylation and early apoptosis. PU.1 and Spi-B regulated Btk
directly as shown by chromatin immunoprecipitation analysis. Ectopic expression of BTK was sufficient to induce apoptosis in
cultured pro–B cells. In summary, these results suggest that PU.1 and Spi-B activate Btk to oppose IL-7 responsiveness in
developing B cells. The Journal of Immunology, 2015, 194: 595–605.
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Materials and Methods
Breeding and care of mice
Breeding and genotyping of CD19+/CreSpi1lox/loxSpib2/2 (referred to as
CD19-CreDPB) mice and CD19+/+Spi1lox/loxSpib2/2 (referred to as DB)
mice were performed as previously described (16). NOD/SCID/gc2/2
(NSG) mice were maintained in a barrier unit at the Western University
Animal Care Facility. NSG mice received 300 cGy radiation 2 h before
receiving a tail vein injection. C57BL/6 mice were purchased from Charles
River Laboratories (Saint-Constant, QC, Canada). Mouse care was monitored under an approved animal use subcommittee protocol in accord with
the Western University Council on Animal Care.

Cell culture
B-ALL or BM cells were cultured in IMDM (Cellgro; Corning, Manassas,
VA) containing 5% IL-7–conditioned medium from the J558L-IL-7 cell
line (21), 10% FBS (BioLogos, Mongomery, IL), 13 penicillin/streptomycin/L-glutamine (Lonza, Shawinigan, QC, Canada), and 5 3 1025 M
2-ME (Sigma-Aldrich, St. Louis, MO). Retroviral vectors encoding Tet3G
and inducible 3XFLAGPU.1 were produced as previously described (22).
Inducible cell lines were maintained in medium containing 0.5 mg/ml
puromycin (BioBasic, Markham, ON, Canada). All cell lines were maintained in 5% CO2 atmosphere and 37˚C.

PCR and genotyping
Relative frequencies of mRNA transcripts were measured by reverse transcription–quantitative PCR (RT-qPCR) and were normalized to the frequency of Gapdh transcripts using the comparative threshold cycle method
(23). For chromatin immunoprecipitation (ChIP) experiments, relative
frequencies of DNA fragments were measured by qPCR performed using
a Rotor-Gene 6000 instrument (Corbett Life Sciences, Valencia, CA).
Amplification of Ig rearrangements was performed as described by Cobaleda
et al. (24). All primer sequences are described in Supplemental Table I.

Flow cytometry and immunoblotting
Flow cytometric analysis and sorting experiments were performed using
FACSCalibur, LSR II, and FACSAria III instruments (BD Immunocytometry Systems, San Jose, CA). The purity of sorted cells was determined
to be $98% upon reanalysis. Data were analyzed using FlowJo 9.1 software (Tree Star, Ashland, OR). Abs were purchased from eBioscience
(San Diego, CA), BioLegend (San Diego, CA), or BD Biosciences (Mis-

sissauga, ON, Canada) and included PE-conjugated anti-CD19 (1D3),
allophycocyanin– or BV421–anti-B220 (RA3-6B2), PE-Cy7–anti-IgM (II/
41), PE–anti-CD93 (AA4.1), FITC–anti-CD23 (B3B4), FITC–anti-CD21
(eBio8D9), allophycocyanin–anti-CD24 (M1/69), PE–anti-CD93 (AA4.1),
FITC– or PE–anti-BP-1 (6C3), biotin–anti-CD3 (145-2C11), allophycocyanin-Cy7– or allophycocyanin–anti-CD43 (1B11), FITC–anti-CD127
(A7R23), FITC–anti-CD45.1 (A20), PE-Cy5.5–anti-CD45.2 (clone 104),
and allophycocyanin–annexin V. Staining of intracellular targets was
performed using the Fix and Perm kit (Life Technologies, Burlington, ON,
Canada) and Phosflow PE anti-pSTAT5 pY694 (BD Biosciences). Live/
dead cell staining was performed with the Live/Dead fixable yellow dead
cell stain kit (Life Technologies). For immunoblotting analysis whole-cell
lysates from enriched splenic B cells were probed with anti-BTK Ab (Cell
Signaling Technology, Whitby, ON, Canada), HRP goat anti-rabbit secondary Ab (Thermo Fisher), and visualized with SuperSignal West Pico
reagent (Thermo Fisher).

Histological and microscopic analysis
Mice were euthanized by lethal i.p. injection of 540 mg/ml sodium pentobarbital (Euthanyl Forte, Bimeda-MTC Animal Health, Cambridge, ON,
Canada). Tissues were fixed in 10% neutral buffered formalin. Femurs were
decalcified for 96 h in 26% formic acid (TBD-2, Thermo Fisher, Pittsburgh,
PA). Tissues were paraffin embedded, sectioned, and stained with H&E.
High-resolution micrographs were captured using a Q-Color3 digital
camera (Olympus, Markham, ON, Canada).

Microarray analysis
RNA was prepared from sorted cells using RNA-Bee (Tel-Test, Friendswood, TX). RNA integrity and purity were checked using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA was processed
using the WT Terminal Labeling and Hybridization kit (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions and analyzed using
Mouse Exon 1.0 ST arrays (Affymetrix) at the London Regional Genomics
Centre. Data analysis was performed using Partek Genomics Suite (Partek,
St. Louis, MO). Batch effect removal was performed using ComBat
software (25). Differentially expressed genes were identified using oneway ANOVA and a cut-off of 1.5-fold with p , 0.05. Heat maps and
volcano plots were generated using Hierarchical Clustering Explorer.
Partek Pathway software was used to identify biological pathways using
the Kyoto Encyclopedia of Genes and Genomes database, and p values
were calculated using a Fisher exact test. Microarray data are available
from the Gene Expression Omnibus under accession no. GSE48891.

ChIP analysis
Mouse splenic B cells enriched by negative selection of CD43-expressing
cells, cultured i660BM cells, or mouse WEHI-279 cells stably expressing
3XFLAG-tagged PU.1 or Spi-B were cross-linked with 1% formaldehyde
for 10 min at room temperature. ChIP was performed as previously described (12) using anti-PU.1 (Santa Cruz Biotechnology), anti-FLAG
(Sigma-Aldrich), or control mouse anti-IgG Ab (Santa Cruz Biotechnology) conjugated to protein G Dynabeads (Invitrogen, Burlington, ON,
Canada). Enrichment was measured using qPCR of DNA immunoprecipitated with anti-PU.1 normalized to anti-IgG, using primers indicated in
Supplemental Table I. Fold enrichment was calculated using the comparative threshold cycle method (23). For ChIP sequencing (ChIP-seq) analysis, chromatin solutions with an average DNA fragment size of ∼200 bp
were generated using a Bioruptor 300 waterbath sonicator (Diagenode,
Sparta, NJ). DNA was quantified using a 2100 Bioanalyzer (Agilent Technologies). Libraries were generated using the Kapa HTP Library Preparation
kit (Kapa Biosystems) as per the manufacturer’s recommendations. Size
selection was performed on a Pippin Prep instrument (Sage Biosciences).
Libraries were quantified using the Quant-iT PicoGreen dsDNA assay kit
(Life Technologies) and the Kapa Illumina GA with Revised Primers–SYBR
Fast Universal kit (D-Mark). Average size fragments were determined using
a LaChip GX (PerkinElmer) instrument. Libraries were sequenced on an
SR100 run on a HiSeq 2000 (Illumina). Two independent ChIP-seq experiments were conducted for PU.1 and Spi-B. Peak finding and data
analysis were performed using Galaxy Suite (26). Peaks were called using
MACS version 1.0.1 (27) with a genome size of 1.9 3 109 bp (MM9) using
input controls. Peaks were called with a tag size set to either 75 (rep1) or
100 (rep2), bandwidth of 300, and a p value cutoff for peak detection of 1 3
1025. Peak Model was generated using an mfold high-confidence enrichment ratio against background of 15. Wiggle files were created using a resolution of 10 bp. Independent experiments were combined and normalized to
call consensus peaks using mmChIP v1.0.0 with a mappable genome size of
191 3 107 and a p value cutoff for peak detection of 1 3 1025 (28). Input.bed
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pressor gene Blnk is a direct target of activation by PU.1 and/or
Spi-B (17). However, it is not clear how reduced PU.1 and Spi-B
predispose developing B cells to malignant transformation in
CD19-CreDPB mice.
Bruton tyrosine kinase (BTK) is a tyrosine kinase that is critically required for pre-BCR/BCR signaling, and when inactivated
by mutation, it is the most frequent cause of human X-linked
agammaglobulinemia (18, 19). Mutation of Btk in mice is not
sufficient to induce leukemia. However, mutation of Btk strongly
synergizes with mutation of Blnk (SLP-65) in mice to induce
leukemia in mice with ∼75% incidence by 16 wk of age (20).
Therefore, Blnk and Btk function as cooperating tumor suppressors in developing mouse B cells.
In the present study, we investigated the developmental origins
and mechanisms of leukemogenesis in CD19-CreDPB mice. Bone
marrow (BM) pro–B cells were increased in frequency in preleukemic CD19-CreDPB mice, and they were leukemia-initiating
cells as determined by transplantation analysis. Bone marrow cells
from preleukemic CD19-CreDPB mice had increased responsiveness to IL-7 in culture that correlated with loss of BTK expression. Induction of PU.1 expression in cultured CD19-CreDPB
pro–B cells induced Btk expression, reduced STAT5 phosphorylation, and led to early apoptosis. PU.1 and Spi-B regulate Btk
directly as shown by chromatin immunoprecipitation analysis.
Finally, ectopic expression of BTK was sufficient to induce apoptosis in cultured CD19-CreDPB pro–B cells. Taken together,
these results suggest that PU.1 and Spi-B activate Btk to oppose
IL-7 responsiveness in developing B cells.

PU.1 AND Spi-B ACTIVATE BRUTON TYROSINE KINASE

The Journal of Immunology
files for mmChip were generated using Convert from BAM to BED tool
v0.1.0 in Galaxy. ChIP-sequence data are available from the Gene Expression Omnibus under accession no. GSE58128.

Statistical analysis
All data are reported as means 6 SD. Statistical significance was determined
using a Student t test on biological replicates unless otherwise indicated.
Values with p , 0.05 were considered significant. Statistical analysis was
performed using Prism 5.0 (Graphpad Software, La Jolla, CA).

Results
Increase in frequency of immature B cells in the BM of
CD19-CreDPB mice

CD19-CreDPB mice. Total B220+ BM cell frequencies were
slightly increased in 6- to 10-wk-old DB mice but were decreased
in 6- to 10-wk-old CD19-CreDPB mice (Fig. 1A, 1C). Frequencies
of B220loCD432IgM+ cells (fraction E immature B cells) were
significantly increased in 6- to 10-wk-old DB and CD19-CreDPB
mice, whereas frequencies of B220hiCD432IgM+ (fraction F
mature recirculating B cells) were significantly decreased (Fig.
1A, 1D). Analysis of BM development was also performed in
mice aged 11–18 wk. Total B220+ BM cell frequencies were
dramatically decreased in 11- to 18-wk-old CD19-CreDPB mice
(Fig. 1E). Frequencies of fraction C pro–B cells and fraction E
immature B cells were dramatically expanded, representing nearly
30 and 50%, respectively, of all B220+ cells in older CD19CreDPB mice (Fig. 1B, 1F). Frequencies of fraction F B cells were
reduced even further in older mice, as previously reported for
mature splenic B cells (16) (Fig. 1B, 1F). In conclusion, immature
B cells were increased in frequency in the BM of adult CD19CreDPB mice preceding overt leukemia.
Enriched fraction C pro–B cells from BM of CD19-CreDPB
mice transfer disease
Increased frequencies of fraction C pro–B cells in CD19-CreDPB
mice suggested that these might represent leukemia-initiating

FIGURE 1. Alterations in the frequency of immature B cells in the BM of CD19-CreDPB mice. (A) Representative frequencies of immature B cell
(Hardy) fractions in BM of 6- to 10-wk-old CD19-CreDPB mice. Markers used are indicated on the axes. The top right two panels indicate the identity of
fractions A–F. Genotypes are indicated on the right. (B) Representative frequencies of immature B cell fractions in BM of 11- to 18-wk-old CD19-CreDPB
mice. Markers used are indicated on the axes. (C) Quantitation of BM B220+ B cell frequencies for groups of five mice of each indicated genotype aged
6–10 wk. Legend is shown in (D). (D) Quantitation of BM B cell fraction frequencies for groups of five mice of each indicated genotype aged 6–10 wk.
Frequencies are expressed as the percentage of all B220+ BM cells. (E) Quantitation of BM B220+ B cell frequencies for groups of five mice of each
indicated genotype aged 11–18 wk. Legend is shown in (D). (F) Quantitation of BM B cell fraction frequencies for groups of five mice of each indicated
genotype aged 11–18 wk. Frequencies are expressed as the percentage of all B220+ BM cells. *p , 0.05, **p , 0.01, ***p , 0.001.
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Deletion of genes encoding PU.1 and Spi-B in B cells (CD19CreDPB mice) leads to impaired B cell development, followed by
B-ALL at 100% incidence and with a median survival of 21 wk
(16). However, the developmental origin of B-ALL in CD19CreDPB mice was not previously examined. BM B cell development was examined in detail using flow cytometry and the
“Hardy” classification system of fractions A–F (29). Both wildtype (WT; C57BL/6) and DΒ (Spib2/2) BM cells were included as
controls because these two types of mice do not develop leukemia.
First, BM cells were prepared from 6- to 10-wk-old WT, DB, or
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Analysis of gene expression in leukemic cells from
CD19-CreDPB mice reveals a pattern of impaired BCR
signaling
Analysis of gene expression can provide important insights into
pathways of oncogenic transformation (31). As a control for PU.1dependent gene expression, cell sorting was used to enrich splenic

CD19+B220+ B cells from the spleen of DB mice (Fig. 4A, left
panel). For the experiment, cell sorting was used to enrich splenic
CD19+B220lo B-ALL cells or residual CD19+B220+ B cells from
leukemic CD19-CreDPB mice (Fig. 4A, right panel). RNA was
prepared from sorted samples from these three groups and analyzed for gene expression using Affymetrix 1.0 ST exon arrays.
Using a cutoff of a 1.5-fold change and p value of ,0.05 by oneway ANOVA, 2908 genes were found to be downregulated and
3477 genes were upregulated in CD19-CreDPB CD19+B220low
B-ALL cells compared with DB control cells. For the top 100 differentially expressed genes, downregulated genes were reduced by
an average of 56-fold and upregulated genes increased by an average of 27-fold (Fig. 4B). Exon-specific analysis confirmed that
the 39 end of the Spi1 transcript encoding PU.1 was reduced by an
average of 20-fold in CD19-CreDPB B-ALL cells, whereas the
59 end was transcribed equivalently, as predicted by the Cremediated deletion of exons 4 and 5 in these mice (16). Gene expression was also compared with residual CD19+B220+ B cells
from CD19-CreDPB mice. Interestingly, these cells showed changes
in gene expression that were intermediate between CD19-CreDPB
CD19+B220low B-ALL cells and DB B cells (Fig. 4C). CD19CreDPB B cells expressed Spi1 transcripts at levels intermediate
between the other two populations, suggesting that these were
B cells with delayed deletion of Spi1 (Fig. 4C).
In the published literature at least 110 genes have been shown
to be directly regulated by PU.1 using biochemical approaches
(32). Of these 110 genes, 44 (40%) were downregulated in CD19CreDPB B-ALL cells compared with controls and 11 (10%) were
upregulated. The remaining 55 genes (50%) were not significantly
altered. Thus, 50% of known PU.1 target genes in this list were
significantly altered in our study (Fig. 4D). Next, gene ontology
analysis was performed. For genes that were upregulated in CD19CreDPB B-ALL cells compared with control DB B cells, the top
two pathways as ranked by enrichment score and p value included
cell cycle and DNA replication. Specific genes that were highly
expressed in CD19-CreDPB B-ALL cells and were confirmed by
RT-qPCR included Il7r (encoding IL-7Ra), Lgr5, Lef1, Enpep

FIGURE 2. Purified fraction C cells from BM of 6-wk-old CD19-CreDPB mice transfer disease to immunodeficient recipient mice. (A) Mature splenic B
cells do not transfer disease. Mature B cells (CD932B220+CD19+Igk+) were enriched from the spleen of 6-wk-old DB or CD19-CreDPB mice by cell
sorting. Sorted cells (5 3 105) were injected i.v. into sublethally irradiated (300 cGy) NSG mice (four per group). Mice were euthanized after 4 mo without
signs of illness. (B) Fraction C pro–B cells (B220+CD24+CD43+BP-1+) were purified from the BM of 6-wk-old DB or CD19-CreDPB mice by cell sorting.
Sorted cells (1 3 105) were injected i.v. into sublethally irradiated (300 cGy) NSG mice (four mice per group). Mice were euthanized upon signs of illness.
Median survival time of NSG mice transplanted with BM fraction C cells from CD19-CreDPB mice was 113.5 d, significantly shorter than that for controls
(p # 0.01 by Mantel–Cox log-rank test). (C) Representative flow cytometric analysis of leukemic mice. BM and spleen from transplanted mice were
analyzed by flow cytometry using the indicated Abs. B-ALL cells were identified by cell surface expression of CD93 and BP-1. **p , 0.01.
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cells. To test this idea, transplantation experiments were performed using sorted cells from 6- to 10-wk-old DB (control) or
CD19-CreDPB mice. First, mature splenic B cells (B220+CD19+
CD932Igk+ cells) were enriched using cell sorting and injected
i.v. into immunodeficient NSG mice (30). Recipient mice receiving 5 3 105 mature splenic B cells of either genotype showed
no signs of illness until the experiment was terminated at 4 mo
(Fig. 2A). Next, NSG mice were transplanted with 105 fraction C
pro–B cells from DB or CD19-CreDPB donors. Fraction C pro–
B cells were enriched by cell sorting using the gating strategy
shown in Fig. 1A. NSG mice injected with DB pro–B cells did not
show signs of disease at any time point (Fig. 2B). In contrast, NSG
mice receiving CD19-CreDPB fraction C pro–B cells became ill
and required euthanasia with a median time of 113.5 d (Fig. 2B).
The spleens of NSG mice receiving CD19-CreDPB fraction C
pro–B cells contained high frequencies of leukemia cells expressing BP-1 and CD93 as determined by flow cytometry (Fig.
2C). Histopathological examination revealed that every tissue
examined in NSG mice receiving CD19-CreDPB pro–B cells was
infiltrated with leukemia cells. Spleen and BM of transplanted
NSG mice showed extensive infiltration of leukemia cells resulting in effacement of the normal architecture (Fig. 3A, 3B). Liver
showed extensive infiltration of leukemia cells throughout the
sinusoids with focal aggregates of leukemia cells in the portal and
periportal regions (Fig. 3B, Supplemental Fig. 1A). The cortex of
the brain showed meningeal invasion of leukemia cells (Fig. 3D,
Supplemental Fig. 1B) whereas pancreatic tissues showed a large
metastatic aggregate of leukemia cells (Fig. 3E). In conclusion,
these results suggest that BM fraction C pro–B cells are leukemiainitiating cells in CD19-CreDPB mice.

PU.1 AND Spi-B ACTIVATE BRUTON TYROSINE KINASE
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genes that were downregulated in CD19-CreDPB B-ALL cells
compared with control DB B cells, the biological pathway with the
lowest p value identified using gene ontology analysis was BCR
signaling. A large number of genes in this biological pathway
were significantly downregulated, including Shp1, Syk, Lyn, Btk,
Blnk, Vav, Rac, Bcap, and Grb2. Several of these downregulated
genes were confirmed by RT-qPCR analysis of three biological
replicates (Fig. 4E). This analysis confirmed downregulation of
Blnk (encoding B cell linker protein), Lyn (encoding the tyrosine
kinase Lyn), and nearly 100-fold downregulation of Btk (encoding
BTK) (Fig. 4B, 4E). Downregulation of Btk was greater when
measured by RT-qPCR than when measured by microarray (Fig.
4E). In summary, analysis of gene expression in CD19-CreDPB
leukemia cells identified Btk and other key genes involved in
BCR signaling as the most significantly downregulated in these
cells.
Altered IL-7 responses in developing B cells from
CD19-CreDPB mice

(encoding BP-1), and Tcfl2 (Fig. 4B, 4E). As expected based on
differential B220 staining, Ptprc (encoding B220) was one of the
most highly downregulated genes (Fig. 4B, 4E). Importantly, for
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FIGURE 3. Leukemia-infiltrated tissues in transplanted NSG mice.
Representative H&E-stained sections were photographed from four mice
analyzed. Left panels show control C57BL/6 tissues for reference. Right
panels show leukemia-infiltrated NSG tissues at low magnification. Scale
bars are indicated for each panel. (A) Spleen. Control and NSG spleen
cross-sections were photographed at an original magnification 34. (B)
BM. Decalcified femur cross-sections were photographed at an original
magnification 320. (C) Liver. Control and NSG mouse sections show liver
triads of portal vein, artery, and bile duct. Original magnification 320. (D)
Brain. Control and NSG mouse sections show cortical sections in the
dorsal–ventral orientation. Original magnification 34. (E) Pancreas.
Original magnification 310.

IL-7Ra was among the most highly increased genes in our analysis (Fig. 4C, 4E). To determine whether immature B cells in the
BM of preleukemic CD19-CreDPB mice had altered responses to
IL-7, unfractionated BM cells from 6- to 8-wk-old WT, DB, or
CD19-CreDPB mice were placed in culture with ST2 stromal cells
and IL-7. Cell counts and passages were performed every 4 d until
proliferation ceased. BM cells from DB and CD19-CreDPB mice
reproducibly generated more proliferating cells than did WT mice
upon initial culture (representative experiment shown in Fig. 5A).
Interestingly, DB and CD19-CreDPB BM cells contained higher
levels of phosphorylated STAT5 upon IL-7 restimulation than did
WT BM cells (Supplemental Fig. 2). However, WT and DB cultures did not continue to proliferate after three passages. In contrast, BM cells from CD19-CreDPB mice proliferated indefinitely
and in all five trials could be readily established as cell lines (Fig.
5A). These results suggested that BM pro–B cells from CD19CreDPB mice had increased IL-7 sensitivity.
Mutation of Btk in mice has previously been shown to lead to
increased IL-7 sensitivity in mouse BM cells (20, 33). Therefore,
we determined whether Btk mRNA transcript levels correlated
with Spi1 mRNA transcript levels during the process of Spi1 deletion under the control of CD19-Cre in cultured CD19-CreDPB
BM cells. RT-qPCR analysis was performed on RNA prepared
from CD19-CreDPB BM cells placed in culture with IL-7 and
passaged up to eight times. At early passage numbers, cultured
CD19-CreDPB pro–B cells expressed high levels of B220
(Fig. 5B, left panels), Spi1 transcripts (Fig. 5C), and Btk transcripts (Fig. 5E). After repeated passage, expression of B220, Spi1,
and Btk were lost (Fig. 5B, right panels, 5C–E). IL7r transcripts
increased on a per cell basis from passage 1 to passage 8 (Fig. 5D).
Cell lines established from the BM of 6-wk-old CD19-CreDPB
mice expressed IL-7Ra, c-Kit, and CD19 (Fig. 5B, 5E). Proliferation of the cells was IL-7–dependent. Two of five cell lines had
detectable Igh rearrangements (Fig. 5G). However, these cell lines
did not express IgH on the cell surface. None of the five lines
established had detectable Igk rearrangements, or expressed Igk
protein on the cell surface. Therefore these cell lines resembled
cultured pro–B cells rather than pre–B cells. In conclusion, the
changes that occurred in cultured CD19-CreDPB BM B cells
during the process of Spi1 deletion, including increased IL-7Ra
expression, reduced B220 expression, and reduced BTK expression, were similar to differences between DB B cells and CD19CreDPB leukemia cells (Fig. 4). These changes might therefore
occur in the BM of CD19-CreDPB mice during the process of Spi1
deletion and precede leukemic transformation.
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PU.1 induces Btk expression and loss of proliferation in
cultured CD19-CreDPB pro–B cells
To determine the consequences of restoring PU.1 expression in
CD19-CreDPB cells, we made use of a doxycycline-inducible
system (22). A BM-derived CD19-CreDPB pro–B cell line,
660BM, was generated as described in Fig. 5. 660BM cells were
IL-7–dependent and rapidly died by apoptosis when deprived of
IL-7. 660BM cells were infected with a retroviral regulator vector
encoding Tet3G and a retroviral response vector encoding PU.1
under the control of a Tet3G-responsive promoter (Fig. 6A). A
clonal cell line termed i660BM was generated by picking a single
GFP+ colony grown in methylcellulose containing IL-7 and puromycin. Spi1 (encoding PU.1) expression could be highly induced in i660BM cells with concentrations of doxycycline as low
as 70 ng/ml (Fig. 6B). Interestingly, 48 h after PU.1 induction,
i660BM cells shrank in size as determined by reduced forward

light scatter (Fig. 6C). Transition of high forward scatter to low
forward scatter cells was doxycycline dose–dependent (Fig. 6D).
All low forward scatter cells stained brightly with annexin V, indicating early apoptosis, whereas high forward scatter cells had
low levels of annexin V staining (Fig. 6E). Induction of PU.1 in
i660BM cells resulted in reduced STAT5 phosphorylation, suggesting that signaling downstream of the IL-7R was inhibited in
these cells (Fig. 6F). In summary, these results show that induction
of PU.1 reduced STAT5 phosphorylation, reduced cell size, and
induced early apoptosis.
PU.1 and Spi-B directly regulate the Btk gene
The promoter region of Btk contains binding sites capable of
interacting with PU.1 (34, 35). To determine whether PU.1 can
induce BTK expression, we performed anti-BTK immunoblot
analysis. Inducible i660BM cells did not express detectable BTK
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FIGURE 4. Gene expression analysis of CD19-CreDPB leukemia suggests impaired BCR signaling. (A) Sort gates for splenic DB B cells and CD19CreDPB B-ALL cells. Three DB B cell samples, three CD19-CreDPB B220loCD19+ B-ALL samples, and two CD19-CreDPB B220+CD19+ residual B cell
samples were collected and analyzed individually by microarray. (B) Volcano plot of changes in gene expression in splenic CD19-CreDPB B-ALL cells
compared with DB B cells. Genes of interest are indicated by arrowheads. (C) Heat map comparing changes in gene expression in splenic CD19-CreDPB
B-ALL cells (DPB B-ALL), splenic CD19-CreDPB B220+ B cells (DPB B), and DB B cells (DB B). The top 50 decreased genes are shown on the left; the top
50 increased genes are shown on the right. (D) Venn diagram showing overlap between published PU.1 target genes and genes downregulated in CD19CreDPB B-ALL cells compared with DB B cells. Of 110 published PU.1 target genes, 44 were significantly downregulated in CD19-CreDPB B-ALL cells.
(E) Confirmation of alternatively expressed mRNA transcripts. RT-qPCR was used to confirm relative upregulation of five indicated genes and downregulation of four indicated genes in CD19-CreDPB B-ALL cells compared with DB B cells. Error bars represent means and SD of three biological
replicates and all had p values # 0.05 by the Student t test.
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protein when cultured without doxycycline. However, BTK was
expressed after PU.1 induction (Fig. 7A). RT-qPCR measurement of gene expression showed that Btk mRNA transcripts
were highly induced by PU.1 (Fig. 7B). To determine whether
PU.1 directly regulates Btk in B cells, we performed anti-PU.1
ChIP experiments. In i660BM cells, interaction of PU.1 with
the Btk promoter was inducible by doxycycline at 24 (Fig. 7C)
and 48 h (Fig. 7D). In mouse splenic B cells, PU.1 was also
found to interact with the Btk promoter as well as with the
Mef2c enhancer as a positive control (Fig. 7E). Therefore, PU.1
was found to interact with the Btk promoter in both pro–B-like
cells and mature B cells. For mouse Spi-B, no ChIP-quality Abs
are currently available. Therefore, to determine whether Spi-B
could also interact with the Btk promoter, we performed ChIPseq analysis using anti-FLAG ChIP in 33 FLAG–tagged PU.1
or Spi-B–infected mouse WEHI-279 cells (L.A. Solomon, S.K.H. Li,
J. Piskorz, L.S. Xu, and R.P. DeKoter, submitted for publication).
Analysis of ChIP-seq data identified nearly identical peaks of
PU.1 or Spi-B interaction near the annotated transcription start site

of Btk (Fig. 7F). These data therefore indicate that Btk may be
regulated by both PU.1 and Spi-B. To determine whether Btk
expression requires PU.1 in vivo, we examined BTK protein levels
by immunoblot of the few B cells that are present in the spleen of
preleukemic CD19-CreDPB mice. We found that BTK protein
levels were reduced in CD19-CreDPB B cells compared with either WT or DB B cells (Fig. 7G). Collectively, these results show
that PU.1 and Spi-B can activate BTK expression in the
B cell lineage.
Restoration of BTK expression was previously shown to induce
apoptosis in cultured leukemia cells lacking BTK expression
(36). To determine whether BTK was sufficient to induce apoptosis in cultured 660BM cells, these cells were infected with
pMSCV-hBTK-FLAG retrovirus encoding BTK and GFP (37)
or pMSCV-IRES-GFP alone as a control. Infection of 660BM
cells with BTK induced early apoptosis by 48 h as determined
by annexin V staining (Fig. 7H, 7I). We conclude that ectopic
expression of BTK in 660BM cells is sufficient to induce early
apoptosis.
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FIGURE 5. CD19-CreDPB BM B cells have increased responsiveness to IL-7. (A) CD19Cre-DPB developing B cells proliferate indefinitely in response
to IL-7. WT, DB, or CD19Cre-DPB BM cells from 6- to 10-wk-old mice of the indicated genotypes were cultured with IL-7 and ST2 stromal cells. Counts
are shown at each passage after being initially established with 1 million cells. (B) B220 expression is downregulated upon passage of CD19Cre-DPB BM
cells. Flow cytometric analysis was performed with the indicated Abs after three or six passages in IL-7 and ST2 cells. (C) Spi1 transcripts (encoding PU.1)
rapidly decline in cultured CD19Cre-DPB BM cells. (D) Il7r transcripts, encoding IL-7Ra, increase in frequency from passage 1 to 8. (E) Cultured
CD19Cre-DPB BM cells express IL-7Ra on their surface. Passage 3 CD19Cre-DPB cells were stained and analyzed for IL-7Ra (CD127) using flow
cytometry. Thin line indicates isotype control; thick line indicates CD127-stained cells. Numbers indicate mean fluorescence. (F) Btk transcripts, encoding
BTK, decrease in frequency from passage 1 to 8. Results shown are one representative of three independent experiments. (G) Cultured CD19-CreDPB BM–
derived cell lines have undetectable Igk rearrangements. PCR analysis was used to detect Igh (upper panel) or Igk (middle panel) rearrangements from
genomic DNA. Type of rearrangement is indicated on the y-axis. CD19 (lower panel) was used as a control. Control was a CD19-CreDPB B-ALL of
polyclonal origin. BM-derived cell line names are indicated on the x-axis.
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Discussion
In the present study, we showed that deletion of the genes encoding PU.1 and Spi-B leads to an alteration of immature B cell frequencies in the BM. Enriched pro–B cells from 6- to 10-wk-old
CD19-CreDPB mice induced leukemia in transplanted recipients,
suggesting that these were leukemia-initiating cells. Analysis of
gene expression in B-ALL cells from CD19-CreDPB mice showed
that PU.1 and Spi-B enforce expression of many genes required
for BCR signaling, including Btk. PU.1 was sufficient to induce
Btk expression in a CD19-CreDPB pro–B cell line. ChIP experiments demonstrate that Btk is directly activated by PU.1 and SpiB. BTK expression was dramatically reduced in splenic B cells
lacking PU.1 and Spi-B. Finally, ectopic expression of BTK was

sufficient to induce apoptosis in cultured pro–B cells lacking PU.1
and Spi-B. Taken together, these results show that PU.1 and Spi-B
are required for BTK expression in B cells, and reduced BTK expression as a consequence of PU.1/Spi-B deletion is associated with
abnormal IL-7–dependent expansion of pro–B cells in the BM.
The present study showed that a key gene dramatically downregulated in B-ALL cells from CD19-CreDPB mice was Btk
(Fig. 6). Btk was previously implicated as a potential target gene
of PU.1 (34, 35), a result that is now confirmed in this study. Our
experiments demonstrated that PU.1 interacts directly with the Btk
promoter in WEHI-279 cells and the pro–B cell line 660BM, and
that Spi-B interacts with the Btk promoter in WEHI-279 cells. It
remains to be determined whether Spi-B interacts with the Btk
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FIGURE 6. Induction of PU.1 expression induces early apoptosis in 660BM cells. (A) Schematic of retroviral vectors used in the inducible PU.1 system.
The regulator vector encodes the Tet3G transactivator protein and GFP whereas the response vector encodes PU.1 and a puromycin resistance gene (Puro).
(B) Spi1 mRNA transcripts encoding PU.1 were induced after 48 h with doxycycline. Spi1 transcript levels were determined using RT-qPCR and expressed
as a percentage of steady-state control Gapdh mRNA transcripts. (C) Loss of high forward scatter i660BM cells upon 72 h of doxycycline induction. Flow
cytometry was used to measure forward light scatter (x-axis) and side scatter (y-axis) after 72 h of doxycycline induction at the indicated concentrations. (D)
Dose response of the percentage of high forward scatter cells (y-axis) compared with doxycycline concentration (x-axis). Flow cytometry was used to
determine high forward scatter versus low forward scatter as shown in (C) 72 h after doxycycline induction. (E) Induction of early apoptosis. i660BM cells
were cultured for 48 h in the presence of IL-7 and doxycycline at the indicated concentrations. Annexin V staining was quantified by flow cytometry. (F)
Reduced STAT5 phosphorylation as a consequence of PU.1 induction. i660BM cells were cultured for 48 h in the presence of IL-7 and doxycycline at the
indicated concentrations. After 48 h, STAT5 phosphorylation (pSTAT5) was quantified by flow cytometry. *p , 0.05, **p , 0.01, ***p , 0.001 as
determined by the Student t test compared with 0 ng/ml doxycycline.
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promoter in pro–B cells. Btk gene expression was directly correlated with Spi1 transcript levels in cultured CD19-CreDPB BM
cells during the process of Spi1 deletion (Fig. 5C, 5E) consistent
with the idea of this gene being PU.1-dependent. In contrast, Btk
transcript levels inversely correlated with Il7r transcript levels
(Figs. 4E, 5D) as well as with IL-7 responsiveness (Fig. 5A).
Deletion of the Btk gene was previously shown to be sufficient to
cause increased IL-7 responsiveness in BM pre–B cells (20). BTK
is a key component of the pre-BCR signaling pathway that
functions to block IL-7R signaling in developing B cells (38). We
note that the 660BM cells used in our study resemble pro–B cells
rather than pre–B cells based on their lack of expression of surface
IgM or Igk. Therefore, BTK may function to oppose IL-7R signaling in pro–B cells that do not yet express a pre-BCR or BCR. In

summary, reduced BTK expression caused by deletion of PU.1
and/or Spi-B may be sufficient to explain why CD19-CreDPB
pro–B cells are hyperresponsive to IL-7 in culture. Increased responsiveness of CD19-CreDPB pro–B/pre–B cells to IL-7 may
also explain why fraction C pro–B cells expand in the BM of
preleukemic mice.
Our laboratory previously showed that Blnk (encoding B cell
linker protein) is a direct target of PU.1 and Spi-B in developing
B cells (17). Loss-of-function mutation of Btk strongly synergizes
with loss-of-function mutation of Blnk in mice to induce B-ALL
in mice with ∼75% incidence by 16 wk of age (20). BM cells from
Btk/Blnk knockout mice have increased sensitivity to IL-7 and
increased ability to proliferate in response to IL-7 (33, 39, 40).
Similar to CD19-CreDPB mice, leukemias from Btk/Blnk knock-
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FIGURE 7. PU.1 and Spi-B directly activate transcription of Btk. (A) Induction of PU.1 and BTK protein by low concentration of doxycycline (Dox) in
i660BM cells. Immunoblot using anti-BTK, anti-PU.1, or anti–b-actin Abs was performed on cells after 48 h of induction using the indicated concentrations of Dox. (B) Btk mRNA transcripts are induced by 48 h with Dox. Btk transcript levels were determined using RT-qPCR and are expressed as
a percentage of steady-state control Gapdh mRNA transcripts. (C and D) ChIP analysis shows that PU.1 interacts directly with the Btk promoter in i660BM
cells after Dox induction. ChIP was performed using anti-PU.1 or IgG (control) Abs and chromatin prepared from i660BM cells induced with 70 ng/ml Dox
for 24 h (C) or 48 h (D). qPCR was used to quantify the Btk promoter in uninduced (0 ng/ml Dox) or induced (70 ng/ml Dox) cells. Statistical analysis was
performed on technical replicates. (E) ChIP analysis shows that PU.1 interacts directly with the Btk promoter in mouse splenic B cells. ChIP was performed
using anti-PU.1 or IgG (control) Abs and chromatin prepared from C57BL/6 mouse–enriched splenic B cells. qPCR was used to quantify the Hprt promoter
as a negative control, Mef2c enhancer as a positive control, or the Btk promoter. (F) ChIP-seq analysis shows that both PU.1 and Spi-B interact with the Btk
promoter in B cells. Murine WEHI-279 lymphoma cells expressing 33 FLAG–tagged PU.1 or Spi-B were analyzed by ChIP-seq. Peaks located within and
near the Btk gene are shown. (G) Western blot showing reduced BTK expression in splenic B cells from 6- to 10-wk-old CD19Cre-DPB mice. Splenic B
cells were enriched from mice of the indicated genotypes and immunoblotted with anti-BTK or anti–b-actin Abs. (H) Ectopic expression of BTK induces
early apoptosis in cultured pro–B cells. 660BM cells were infected with the MSCV (control) or MSCV-hBTK (encoding BTK) retroviral vectors and
analyzed after 48 h using flow cytometry for annexin V staining. The marker indicates the frequency of cells staining highly with annexin V. (I) Mean and
SD of five biological replicate experiments. The y-axis indicates the frequency of annexin Vhi cells gated on GFP+ infected 660BM cells. *p , 0.05, ***p ,
0.001 using a paired two-tailed t test.
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out mice express BP-1, CD43, and IL-7R and can be readily
cultured as cell lines in response to IL-7 (9, 20). Taken together,
these similarities suggest that reduced expression of both BLNK
and BTK, as a consequence of PU.1 and Spi-B deletion, may
explain why developing CD19-CreDPB B cells are susceptible to
malignant transformation. It is still not fully understood why
reduced BTK and BLNK lead to leukemia in mice. It has been
speculated that the mechanism might involve prolonged transit
through the V(D)J recombination process, leading to accumulation of undesired mutations (41). Expression of an Igh transgene prevents leukemia in Btk/Blnk knockout mice, possibly
because this accelerates transition through Ig recombination
(41). We note that B-ALL cells from CD19-CreDPB mice express high levels of RAG-1 and RAG-2 as determined by
microarray analysis (11- and 9-fold higher than control cells,
respectively). More investigation will be needed to determine
whether ongoing Ig recombination in CD19-CreDPB B cells
plays a role in leukemic transformation.
To summarize, we propose a model to explain why deletion of
PU.1 and Spi-B in the B cell lineage leads to impaired B cell
development and eventually B-ALL. In CD19-CreDPB mice, the
Spi1 gene is deleted starting at the pro–B cell stage under the
control of CD19. Pro–B cells that delete Spi1 downregulate expression of the target genes Btk and Blnk. Reduced BTK and
BLNK expression would in turn result in increased IL-7R sensitivity, leading to increased proliferation of pro–B and large pre–
B cells. Additionally, reduced BTK and BLNK might lead to
delayed V(D)J recombination, leading to accumulation of mutations. Most cells that delete Spi1 likely do not progress past the
pre–B cell stage due to impaired BTK/BLNK-dependent preBCR signaling. We speculate that leukemia arises in rare progenitor cells from the late pro–B/early pre–B fraction C and C9
compartments.
There are a number of similarities between the CD19-CreDPB
mouse model of B-ALL and human precursor B-ALL. Mutations
in SPI1 encoding human PU.1 have been identified in relapsed
precursor B-ALL (13), and repression of SPIB encoding human
Spi-B is associated with human precursor B-ALL (14). Btk and
Blnk were found to be targets of PU.1 and Spi-B in our studies,
and they are established as tumor suppressors in human precursor B-ALL (36, 42). Expression of the IL-7R has long been
known to be a common feature of human childhood or adult
B cell leukemia (43, 44). Finally, although IL-7 has been previously suggested to be not required for human B cell development, gain-of-function mutations in the human IL7R gene are
associated with precursor B-ALL (45, 46). These correlations
lead us to expect that further studies using the CD19-CreDPB
mouse model will lead to elucidation of the biochemical pathways that may explain how precursor B-ALL arises in human
patients.
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